A higher dose influenza vaccine can lead to better seroprotection in patients with plasma cell dyscrasia, according to a study involving 51 individuals.

Participants—all of whom had plasma cell dyscrasia—were treated with 2 doses of a high-dose influenza vaccine. Investigators looked at the rate of confirmed flu infections, as well as factors linked with seroprotection. Among the results:

• 6% of patients experienced lab-confirmed flu.
• Rates of seroprotection against influenza B, H1N1, and H3N2 increased from 4% at baseline to 49% after 1 dose, and 65% after 2 doses.
• Patients with plasma cell disorder requiring therapy, <partial response, or receiving conventional chemotherapy had lower likelihood of seroprotection.
• Patients receiving an immunomodulatory drug with or without a proteasome inhibitor were more likely to be protected.